Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center

BACKGROUND: Vedolizumab (VDZ), an adhesion molecule inhibitor and infliximab (IFX), a tumor necrosis factor (TNF) blocker, are both approved as first-line induction agents in moderately to severely active ulcerative colitis (UC). However, there are no head-to-head studies comparing the relative effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Allamneni, Chaitanya, Venkata, Krishna, Yun, Huifeng, Xie, Fenglong, DeLoach, Lindsey, Malik, Talha A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827901/
https://www.ncbi.nlm.nih.gov/pubmed/29511405
http://dx.doi.org/10.14740/gr934w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827901/
https://www.ncbi.nlm.nih.gov/pubmed/29511405
http://dx.doi.org/10.14740/gr934w

Ejemplares similares